Cohance Lifesciences Limited submitted a regulatory disclosure to the National Stock Exchange of India Limited and BSE Limited regarding the outcome of a USFDA inspection at its formulation manufacturing facility.

The company provided an update on the USFDA inspection that was previously communicated on 5 September 2026. The inspection was conducted at the company's formulation (FDF) manufacturing facility located at Shamshabad, Telangana, which carries FEI No. 3019037664.

USFDA has issued the Establishment Inspection Report (EIR) for this facility and has classified the inspection outcome as Voluntary Action Indicated (VAI). With the receipt of the EIR, the inspection process stands concluded.

The disclosure was signed by Sisir K Mishra, Company Secretary and Compliance Officer, who digitally signed the document on 21 November 2026 at 09:34:03 +05'30'.